BioSpace News Archive

OncoHost today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases.

Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the nation’s largest provider-driven health care performance improvement company.

Copernic Catalysts, Inc. (Copernic) today announced an exclusive four-year research collaboration with Schrödinger, Inc. to help accelerate the discovery and development of sustainable catalysts for applications in e-fuels and bulk chemicals.

The Scleroderma Research Foundation, the nation’s largest non-profit funder of scleroderma research, announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.

MAIA Biotechnology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for THIO to be evaluated in the U.S. as part of THIO-101, the Company’s ongoing global phase 2 clinical study in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

Yield10 Bioscience, Inc. announced that the harvest of a majority of the winter and spring Camelina sativa grain produced under grower contracts in 2022/2023 has been completed.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) today announces that its registration-enabling pivotal Phase 3 study of its lead clinical candidate, Bria-IMT™, in combination with an immune check point inhibitor, is fully approved by the Institutional Review Board (IRB) and will soon enroll patients with advanced metastatic breast cancer.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first patient in its theranostic 64Cu/67Cu SAR-Bombesin Phase I/II trial in metastatic castrate resistant prostate cancer (mCRPC).

Akura Medical, a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing.

Trace Medical, the national leader in advanced respiratory rentals and biomedical services, has announced a long-term distribution agreement with Outset Medical to rent the Tablo® Hemodialysis System to Home Medical Equipment (HME) providers.